Stock Details
DSKYF is Daiichi Sankyo Company, Limited's stock. Stock exchange Other OTC (Currency USD). Average price in 50 days is 23.04$. Average daily volumn in 3 months 3.09k. Market cap 44.97B



Stock symbol : DSKYF. Exchange : Other OTC. Currency : USD
Lastest price : 25.59$. Total volume : 1.49k. Market state CLOSED
Click reload if you want to check the lastest price on market!!!

Daiichi Sankyo Company, Limited (DSKYF)
Last Price
25.59$
Change
0.30
Volume
1.49k

Previous Close25.29
Open25.87
Day Range25.59-25.87
Bid0.00 x N/A
Ask0.00 x N/A
Volume1.49k
Average Volume3.09k
Market Cap44.97B
Beta0.73
52 Week Range17.61-28.93
Trailing P/E93.74
Foward P/E67.34
Dividend (Yield %)0.83%
Ex-Dividend Date2022-09-29



Financial Details


According to Daiichi Sankyo Company, Limited's financial reports the company's revenue in 2022 were 1.04T an decrease( +3.95%) over the years 2021 revenue that were of 962.52B. In 2022 the company's total earnings were 66.97B while total earnings in 2021 were 75.96B(-12%).


Loading ...



Organization

Daiichi Sankyo Company, Limited researches and develops, manufactures, imports, markets, and sells pharmaceutical products worldwide. The company offers trastuzumab deruxtecan, an anti-cancer agent and anti-HER2 antibody drug conjugate; mirogabalin for pain treatment; teneligliptin/canagliflozin for type 2 diabetes mellitus treatment; lacosamide anti-epileptic agent; prasugrel, an antiplatelet agent; denosumab for osteoporosis and bone disorders; teneligliptin for type 2 diabetes mellitus treatm... ent; edoxaban, an anticoagulant; esomeprazole for ulcer treatment; memantine for treating Alzheimer's disease; and laninamivir for anti-influenza treatment. It also provides olmesartan, an antihypertensive agent; levofloxacin, an antibacterial agent; pravastatin for hypercholesterolemia treatment; and loxoprofen, an anti-inflammatory analgesic. In addition, the company offers colesevelam for treating hypercholesterolemia and type 2 diabetes mellitus treatment; and ferric carboxymaltose and iron sucrose injections for treating anemia. Further, it provides Lulu, a combination cold remedy; Loxonin S, an antipyretic analgesic /anti-inflammatory analgesic; Transino for melasma improvement and treating against spots and freckles; Minon, a skincare product; and Breath Labo and Clean Dental oral care products, as well as Silodosin for dysuria; Gefitinib for malignant tumours; Bicalutamide for prostate cancer; and Tamoxifen, an anti-breast cancer agent. Additionally, the company offers adsorbed cell culture-derived influenza, influenza HA, measles rubella combined, and mumps vaccines. It also provides pharmaceuticals and drugs for animals, cosmetics, medical equipment, food products, drinking water, active pharmaceutical ingredients, and intermediates. It has collaboration with Guardant Health to develop Guardant360 CDx as a companion diagnostic for Enhertu in advanced metastatic non-small cell lung cancer. The company was founded in 1899 and is headquartered in Tokyo, Japan.

Market Cap:
44.97B
Revenue:
1.04T
Total Assets:
2.22T
Total Cash:
662.48B


News about "Daiichi Sankyo Company, Limited"

Daiichi Sankyo Company, Limited (OTCMKTS:DSNKY) Sees Large Increase in Short Interest

Source from : Defense World - 11 days ago

Daiichi Sankyo Company, Limited (OTCMKTS:DSNKY – Get Rating) was the target of a significant increase in short interest in the month of April. As of April 30th, there was short interest totalling 294, ...See details»


Daiichi Sankyo Company, Limited (DSKYF) CEO Sunao Manabe on Q4 2021 Results - Earnings Call Transcript

Source from : Seeking Alpha - 26 days ago

And in ASCA and in China, we signed an agreement to transfer Cravit and Daiichi Sankyo Pharmaceutical Beijing Co., Ltd. We will continue to strengthen our transformation to a profit structure ...See details»


Daiichi Sankyo Co. Ltd.

Source from : Wall Street Journal - 10 days ago

Earnings Per Share (TTM) A company's net income for the trailing twelve month period expressed as a dollar amount per fully diluted shares outstanding. Market Capitalization Reflects the total ...See details»


Daiichi Sankyo Co Ltd - Stock Ownership DSKYF

Source from : Morningstar%2c Inc. - 17 days ago

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.See details»


DSNKY Daiichi Sankyo Company, Limited

Source from : Seeking Alpha - 13 days ago

The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.See details»


ViGeneron announces follow-on collaboration with Daiichi Sankyo to develop a novel gene therapy for prevalent eye diseases

Source from : Yahoo News UK - 1 days ago

today announced a follow-on collaboration with Daiichi Sankyo Company, Limited (“Daiichi Sankyo”) to utilize ViGeneron’s novel engineered recombinant adeno-associated virus vectors (vgAAVs) to address ...See details»


Daiichi Sankyo Provides Update on Patent Dispute With Seagen

Source from : thedailytimes - 1 month ago

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Apr 8, 2022-- Daiichi Sankyo Co., Ltd. (TSE: 4568) announced today that a jury in the U.S. District Court of Eastern District of Texas decided that ...See details»


Seagen Announces Jury Award in Patent Infringement Case Against Daiichi Sankyo

Source from : The Globe and Mail - 1 month ago

Seagen Inc. (Nasdaq: SGEN) today announced that a jury in the U.S. District Court for the Eastern District of Texas found that Daiichi Sankyo Co. Ltd. (“Daiichi Sankyo”) infringed Seagen’s U ...See details»


fda-approves-astrazeneca-daiichi-sankyos-enhertu-in-breast-cancer-image

FDA Approves AstraZeneca, Daiichi Sankyo’s ENHERTU in Breast Cancer

Source from : Contract Pharma - 18 days ago

Phase III trial showed ENHERTU reduced the risk of disease progression or death by 72% versus trastuzumab emtansine.See details»


FDA Gives Regular Approval to AstraZeneca’s and Daiichi Sankyo’s Enhertu for HER2-Positive Breast Cancer

Source from : FDAnews - 17 days ago

With the change to regular approval, Enhertu can now be used in earlier lines of treatment in patients with HER2-positive metastatic breast cancer.See details»


AstraZeneca, Daiichi Sankyo cancer drug secures US regulatory boost

Source from : London South East - 26 days ago

AstraZeneca said the Enhertu drug, developed alongside Daiichi Sankyo Co Ltd, secured the US regulatory win. Daiichi Sankyo is a pharmaceutical company based in Tokyo, Japan. Enhertu treats ...See details»


Daiichi Sankyo Company, Limited (OTCMKTS:DSNKY) Short Interest Update

Source from : ETF Daily News - 1 month ago

Daiichi Sankyo Company, Limited (OTCMKTS:DSNKY – Get Rating) was the target of a large growth in short interest in the month of March. As of March 31st, there was short interest totalling 9,500 ...See details»


Daiichi Sankyo Co., Ltd.

Source from : ニッケイ・エイジア - 13 days ago

Daiichi Sankyo Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceuticals. Its products include drugs for the field of oncology such as Trastuzumab deruxtecan ...See details»


ViGeneron announces follow-on collaboration with Daiichi Sankyo to develop novel gene therapy for prevalent eye diseases

Source from : Pharmabiz - 25 days ago

ViGeneron GmbH, a next-generation gene therapy company, announced a follow-on collaboration with Daiichi Sankyo Company, Limited (Daiichi Sankyo) to utilize ViGeneron’s novel engineered recombinant ...See details»